PATH | VRL
Menu

Immunogenicity and Safety of a New Meningococcal A Conjugate Vaccine in Indian Children Aged 2-10 Years: A Phase II/III Double-Blind Randomized Controlled Trial

This article, published in Vaccine, describes a study that compared the immunogenicity and safety of a single dose of a new meningococcal A conjugate vaccine (PsA-TT, MenAfriVac™, Serum Institute of India Ltd.) against the meningococcal group A component of a licensed quadrivalent meningococcal polysaccharide vaccine (PsACWY, Mencevax ACWY®, GlaxoSmithKline) 28 days after vaccination in Indian children. The article concludes that MenAfriVac™ is well tolerated and significantly more immunogenic when compared to the licensed polysaccharide vaccine in 2- to 10-year-old Indian children. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Hirve S, Bavdekar A, Pandit A, et al.

Published: 2012

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and Safety of a New Meningococcal A Conjugate Vaccine in Indian Children Aged 2-10 Years: A Phase II/III Double-Blind Randomized Controlled Trial. Vaccine. 2012;30(45):6456-6460.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease/vaccine specific information

Regions: Asia